Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials

Citation
Ghosh-Swaby OR, Goodman SG, Leiter LA, et al. Lancet Diabetes Endocrinol 2020;8:418–35.